Compare ClearPoint Neuro Inc (CLPT) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs iShares China Large-Cap ETF — how do they compare? ClearPoint Neuro Inc trades at $14.61 (market cap $454.21M), while iShares China Large-Cap ETF trades at $35.23. Which is the better fit depends on your goals.
| CLPT | FXI | |
|---|---|---|
Market Cap | $454.21M | — |
Sector | Health | — |
52-Week High | $29.60 | $41.75 |
52-Week Low | $8.66 | $31.59 |
Enterprise Value | $488.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
FXI, the iShares China Large-Cap ETF, trades at $35.26, down 3.37% on the day, reflecting recent pressure on Chinese equities. Technical indicators show a bullish moving average signal but neutral oscillators, with key resistance at $37. Recent news highlights China's export strength and state-backed economic support, though geopolitical tensions and U.S. restrictions pose headwinds. The ETF offers exposure to China's financial and industrial giants, with a dividend scheduled for June 2026.
The outlook for FXI is mixed; bullish technical trends and China's policy support may drive gains, but risks include U.S.-China tensions and domestic economic volatility. Investors should weigh diversification benefits against regulatory and macroeconomic uncertainties, with Wall Street sentiment cautious amid fluctuating analyst views.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
